Most Read Articles
04 Oct 2018
A week of preoperative oral antibiotics prior to percutaneous nephrolithotomy does not appear to confer any benefit in patients at low risk for infectious complications, suggests a recent study. Perioperative antibiotics according to the American Urological Association (AUA) Best Practice Statement is deemed sufficient.
6 days ago
The use of statins does not appear to influence the immature platelet count in patients with coronary artery disease (CAD), a new study has shown.
Rachel Soon, 01 Sep 2018

MIMS Pharmacist presents an overview of a standardized extract of Pinus pinaster bark, and its potential role in slowing down the progression of diabetic retinopathy.

Dr. Lau Hui Ling, 01 Aug 2017
Oral contraceptive selection should be individualized for each patient to yield maximum benefit.

Dual inhibition of EGFR, HER3 confers no survival benefit in metastatic colorectal cancer

10 Jun 2018

The dual-action antibody directed against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), duligotuzumab, does not appear to provide survival advantage compared with cetuximab in patients with RAS exon 2/3 wild-type metastatic colorectal cancer (mCRC) treated with the FOLFIRI (folinic acid, fluorouracil and irinotecan) regimen, according to the results of a phase II trial.

A total of 134 mCRC patients (median age 62 years; 61 percent male) with KRAS exon 2 wild-type were randomized to receive either duligotuzumab (n=68) or cetuximab (n=66) with FOLFIRI until progression or intolerable toxicity. Researchers performed mutation and biomarker analysis on mandatory tumour samples, as well as efficacy analysis in patients with RAS exon 2/3 wild-type tumours.

Of the patients, 98 had RAS exon 2/3 wild-type tumour, with 53 in the duligotuzumab arm and 45 in the cetuximab arm.

Efficacy data revealed that in the subgroup of patients with RAS wild-type tumours, duligotuzumab did not improve progression-free survival (median PFS, 7.3 vs 5.7 months; stratified hazard ratio [HR], 1.21; 90 percent CI, 0.81–1.81) or overall survival (median OS, 14.0 vs 13.1 months; stratified HR, 1.00; 0.61–1.66) compared with cetuximab. Moreover, a trend toward a lower objective response rate (ORR) was observed in the duligotuzumab arm (19 percent vs 33 percent; stratified HR, 0.47; 0.21–1.01).

There was no association observed between PFS or ORR and ERBB3, NRG1 or AREG expression. In terms of safety, duligotuzumab was associated with fewer skin rash events but more diarrhoea. Additionally, although the incidence of grade ≥3 adverse events (AEs) was similar between the two treatment arms, the frequency of serious AEs was higher with duligotuzumab.

Further development of duligotuzumab has been discontinued.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
04 Oct 2018
A week of preoperative oral antibiotics prior to percutaneous nephrolithotomy does not appear to confer any benefit in patients at low risk for infectious complications, suggests a recent study. Perioperative antibiotics according to the American Urological Association (AUA) Best Practice Statement is deemed sufficient.
6 days ago
The use of statins does not appear to influence the immature platelet count in patients with coronary artery disease (CAD), a new study has shown.
Rachel Soon, 01 Sep 2018

MIMS Pharmacist presents an overview of a standardized extract of Pinus pinaster bark, and its potential role in slowing down the progression of diabetic retinopathy.

Dr. Lau Hui Ling, 01 Aug 2017
Oral contraceptive selection should be individualized for each patient to yield maximum benefit.